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Abstract
The marked overexpression of cyclin-dependent kinase 5 (CDK5) or Notch1 receptor, which plays critical roles in pancreatic ductal adenocarcinoma (PDAC) development, has been detected in numerous PDAC cell lines and tissues. Although, a
previous study has demonstrated that CDK5 inhibition disrupts Notch1 functions in
human umbilical vein endothelial cells, the mechanism underlying Notch1 activation regulated by CDK5 remains unclear. Herein, we identified a physical interaction
between CDK5 and Notch1 in PDAC cells, with the Notch1 peptide phosphorylated
by CDK5/p25 kinase. CDK5 blockade resulted in the profound inhibition of Notch
signaling. Accordingly, CDK5 inhibition sensitized PDAC cell proliferation and migration following Notch inhibition. In conclusion, CDK5 positively regulates Notch1
function via phosphorylation, which in turn promotes cell proliferation and migration.
The combinational inhibition of CDK5 and Notch signaling may be an effective strategy in the treatment of PDAC.
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IN T RO D U C T IO N

Pancreatic ductal adenocarcinoma (PDAC) is a disease of
nearly complete lethality presenting a median survival time
of 6 months, and is predicted to become the second leading
cause of cancer-related deaths before 2030.1 This may be explained by the vast majority of patients presenting with advanced stages of PDAC at diagnosis, and PDAC cells possess
a high metastatic potential and are often resistant to available
cytotoxic drugs.2 Thus, there is an urgent need to identify

aberrant signaling pathways that present suitable substrates
for targeted therapies.
Notch signaling is an evolutionarily conserved cell fate
determination pathway that has great relevance in multiple
aspects of cancer biology.3 It promotes the initiation and progression of PDAC and could be a valuable target in PDAC
therapy.4,5 Furthermore, it is a juxtacrine cell-cell communication pathway that positively or negatively affects cellular proliferation, survival, differentiation, and apoptosis in a
context-dependent manner. Notch1 is present at the cell surface as a heterodimeric molecule (p120/p200), comprising an

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Cancer Medicine. 2021;10:3689–3699.		

wileyonlinelibrary.com/journal/cam4

|

3689

3690

|

  

extracellular domain (p200) involved in ligand binding and a
cytoplasmic domain (p120) involved in signal transduction.
The precursor Notch1 protein (p300) is cleaved into extracellular and cytoplasmic domains in the trans-Golgi network by
furin. Ligand binding triggers a cascade of prototypic cleavage events and finally releases the Notch intracellular domain
(NICD). Then, the NICD is translocated into the nucleus and
binds to the DNA-binding protein CBF1, leading to the transcriptional activation of multiple effector genes such as those
encoding members of the HES/HEY family.6 Although, the
molecular components of Notch signaling have been well defined, and signaling from the cell surface to the genome is
simple and linear, the mechanisms regulating Notch activity
need to be comprehensively elucidated.6
Cyclin-
dependent kinase 5 (CDK5) is also known to
contribute to PDAC formation and progression.7 This
proline-directed serine/threonine kinase is activated following association with either one of two noncyclin activator
proteins, p35 and p39. The cleavage of p35 and p39 to p25
and p29, respectively, yields activators with greater stability
and increased CDK5 kinase activation when compared with
that of observed with the full-length forms of p35 and p39.7
CDK5 is mainly activated by p35 or its truncated product,
p25, and the active CDK5/p25 kinase is present in Golgi
membranes in neurons.8,9 Although, the role of CDK5 in the
central system is well characterized, it has been recently associated with the development and progression of multiple
cancers, including brain, breast, lung, colon, and pancreatic
cancer.7,10 Accumulating evidence has implicated CDK5 as
an important determinant of malignant progression, invasion, and metastasis in PDAC.11,12 CDK5 is widely active,
and p35 and p39 are significantly overexpressed in PDAC.13
Thus, both CDK5 and Notch1 are important proteins that affect PDAC cell growth, invasion, and metastasis. In the current study, we investigated the crosstalk between CDK5 and
Notch1 signaling in PDAC cells.
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2.1
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M ATE R IA L S A N D ME T HODS
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Cell culture and chemical compounds

Human BxPC-3 and HPAC PDAC cells were obtained from
National Infrastructure of Cell Line Resource (Beijing,
China) and were grown in DMEM (Dulbecco's Modified
Eagle's medium) supplemented with 10% fetal bovine
serum (Cat#900-
108, Gemini), 100 units/mL penicillin,
and 100 mg/mL streptomycin (Cat#15140122, HyClone) at
37°C in humidified air with 5% CO2. siRNAs and plasmids
were transfected using Lipofectamine 2000 (Cat#11668030,
Invitrogen) according to the manufacturer's instructions.
Roscovitine (Cat#R7772, Sigma) was used to inhibit CDK5
kinase activity. The γ-secretase inhibitor DAPT (Cat#D5942,
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Sigma) was used to prevent Notch cleavage and nuclear entry.
The inhibitors were diluted in dimethyl sulfoxide (DMSO),
which was also used as a control.

2.2 | Co-immunoprecipitation and
immunoblotting assay
Cells were washed with cold PBS, collected by scraping, and
lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 0.3% Nonidet P-40, and 2 mM EDTA) containing
protease inhibitor cocktail (Cat#HY-
K0011, MCE). Cells
were lysed on ice for 40 min, followed by centrifugation at
12000 × g for 40 min at 4°C, and the supernatant was removed. For immunoprecipitaion, 1 mg of protein was incubated with 2 μg of specific antibodies at 4°C overnight.
Subsequently, 30 μL protein A/G agarose (Cat#sc-
2003,
Santa Cruz Biotech) was added, and samples were incubated at 4°C for 2 h. Beads were then washed five times
using the lysis buffer. Between washes, the beads were collected by centrifugation at 1000 × g for 3 min at 4°C. The
precipitated proteins were eluted from the beads by resuspending the beads in 2 × protein loading buffer and boiling for 10 min. Immunoblotting was then performed. For
routine immunoblotting, cells were washed twice with cold
PBS, then lysed in RIPA buffer. Equal amounts of protein
were loaded onto SDS–PAGE and transferred onto polyvinydene fluoride (PVDF) blotting membranes. The membranes were blocked with 5% fat-free milk then probed with
indicated antibodies at 4°C. The primary antibodies were as
follows: anti-Notch1 (Cat#sc-32756, Santa Cruz Biotech),
anti-CDK5 (Cat#LS-B353, LifeSpan BioSciences), anti-p35
(Cat#41304, Signalway), anti-HA (Cat#sc-7392, Santa Cruz
Biotech), and anti-β-actin (Cat#66009, Proteintech Group).
Members were then washed and incubated with anti-rabbit
or anti-
mouse horseradish peroxidase-
conjugated antibodies (Cat#SA00001-
1, SA00001-
2, Proteintech Group)
for 1 h at room temperature. Signals were detected using
a chemiluminescence Western Blot scanner (ChampGel
7000, SAGECREATION). Protein levels were normalized to β-actin levels and quantified using ImageJ software.
Densitometry analyses of the blots for Figure 3 were in
Figure S2.

2.3

|

RNA extraction and expression analysis

Total RNA from HPAC and BxPC-3 cells that had undergone indicated treatment was isolated using Trizol
(Cat#15596018, Invitrogen). For reverse transcription and
polymerase chain reaction (RT-PCR), first-strand cDNA
was synthesized form 1 μg of total RNA using SuperScript
Kit (Cat#18091050, Invitrogen) according to the supplier's
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manual. Quantitative RT-
PCR was performed using a
®
SYBR Green Realtime PCR Master Mix (Cat#QPK-201,
Toyobo) and an Mx3000P instrument (Stratagene
Laboratories). The primer sequences for qPCR are listed
in Table 1.

2.4 | DNA constructs, site-directed
mutagenesis, and siRNA-mediated
CDK5 knockdown
Wild-
type CDK5 was cloned into the pCDNA3.1 vector.
Point mutations were established using the Q5 Site-Directed
Mutagenesis Kit (Cat#E0554, New England Biolabs) with
primer pairs matching target regions. The following primers were used for mutagenesis: D144 N forward primer,
5’-GAAATTGGCTAATTTTGGCCTGG-3’ and reverse
primer, 5’-AGCTCCCCATTCCTGTTTATTAG-3’; and K33 T
forward primer, 5’-GTGGCTCTGACACGGGTGAGG-3’
and reverse primer, 5’-GATCTCATGAGTCTCCCGG-3’.
siRNA specific for CDK5 was synthesized by Shanghai
GenePharma Co., Ltd. (Shanghai, China). The CDK5 siRNA
sequence was 5’-GGGAGAUCUGCCUACUCAATT-3’.
The negative control siRNA (NcRNA) sequence was
5’-UUCUCCGAACGUGUCACGUTT-3’.

2.5

|

Immunofluorescence

For cells immunostaining, cells were rinsed twice in PBS and
fixed for 15 min in 4% paraformaldehyde/PBS at room temperature. After rinsing, permeabilization was achieved in 0.4%
Triton X-100/PBS for 20 min. Indicated antibodies incubation
were performed in PBS overnight at 4°C, following blocking
in 10% serum/PBS for 10 min. After being rinsed in PBS, cells
were incubated with Alexa Fluor 488-conjugated anti-mouse
IgG (Cat#R37120, Invitrogen) and Alexa Fluor 594-conjugated
anti-rabbit IgG (Cat#R37117, Invitrogen) for 1 h at room temperature. Cells were DAPI-treated to stain nuclei and mounted
with anti-fade medium. Images were captured using a confocal
laser-scanning microscope (LSM880, Carl Zeiss).

TABLE 1
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Human pancreatic cancer tissue microarrays were purchased from Xi'an Alena Biotechnology Co., Ltd. of China.
Following dewaxing, rehydration and antigen retrieval, the
samples were stained with Notch1 and CDK5 antibodies
at 4°C overnight. The samples were then incubated with
Alexa Fluor 488-conjugated anti-rabbit IgG (Cat#R37118,
Invitrogen) and Alexa Fluor 594-
conjugated anti-
mouse
IgG (Cat#R37121, Invitrogen) for 1 h at room temperature.
Nuclei were conterstained with DAPI. The stained tissues
were visualized using a confocal laser-scanning microscope
(LSM880, Carl Zeiss).

2.6 | In vitro kinase assays and mass
spectrometry
Assays were performed using 100 µM Notch1 peptide
(LifeTein, Beijing, China) and 7.8 nM CDK5/p25 (Cat#14-
516-M, Sigma) in 5 mM MOPS (pH 7.2), 5 mM MgCl2,
1 mM EGTA, 0.4 mM EDTA, 0.25 mM DTT, 50 ng/μL BAS,
and 100 µM ATP. The reactions were performed for 30 min
at 32.6°C. Following the kinase assays, the Notch1 peptide
was subjected to TiO2 affinity chromatography according
to the manufacturer's manual (GL Sciences, Eindhoven,
Netherlands). Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) was performed using a Q Exactive
mass spectrometer (Thermo Fisher Scientific, USA). The
peptide-based enzyme activity assay is a highly sensitive and
convenient method.14

2.7 | Expression and survival analysis using
GEPIA web tool
The online database Gene Expression Profiling Interactive
Analysis (GEPIA, http://gepia.cancer-pku.cn/) was used to
analyze Notch1, CDK5, p35, and p39 RNA sequencing expression data based on The Cancer Genome Altas (TCGA)
and the Genotype-Tissue Expression (GTEx) projects.15 The
overall survival analysis was performed using Kaplan–Meier
in the GEPIA dataset.

Sequences of the primers for qPCR

Gene

Forward primers

Reverse primers

p35

5’-CCAGAACAACATCACGCACC −3’

5’-GGGTGAGGGGCTTTCTTGAC −3’

CDK5

5’-GCACAAGAACATCGTCAGGC −3’

5’-TTGGCCCCAAAGAGGACATC −3’

Notch1

5’-GCAGTTGTGCTCCTGAAGAA −3’

5’-CGGGCGGCCAGAAAC −3’

Hes1

5’-TGATTTTGGATGCTCTGAAGAAAGATA−3’

5’-GCTGCAGGTTCCGGAGGT−3’

C-Met

5’-GTAAGTGCCCGAAGTGTA−3’

5’-TTTCTTGCCATCATTGTC−3’

β-actin

5’-GTGACGTGGACATCCGCAAAGAC−3’

5’-TCAAGAAAGGGTGTAACGCAACTAA−3’
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2.8 | Cell metabolism viability,
proliferation, and migration assay
BxPC-3 and HPAC cells were inoculated in 96-w ell culture plates, and cell viability was evaluated by reduction
of MTT tetrazolium salt [3-( 4, 5-d imethylthiazol-2 -y l)-2 ,
5-d iphenyltetrazolium bromide] (0.5 mg/ml) by viable
cells to form purple formazan product after 2 h incubation. Experiments were performed in triplicate on indicated conditions, and repeated at least three times.
For a colony assay, 1000 cells were plated in six-well
plates to assess the effect of CDK5 and/or Notch inhibitors
on colony formation after 10 days of incubation at 37°C in
5% CO2 incubator.
For a migration assay, HPAC cells were seeded in a six-
well plate (2 × 105 cells/well) and incubated for 24 h. A
scratch was made using a 1-mL pipette tip, followed by treatment of cells with indicated inhibitors. Images were captured
at 0 and 48 h using an inverted microscope. ImageJ software
was used to calculate the area of the scratch. Then, the percentage of wound closure was calculated and compared with
that of the control.

CHU et al.
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2.9

Statistical analysis

Data are presented as the mean ±standard deviation.
Comparisons between control and target data sets were performed using independent sample t-tests, with P-values less
than or equal to 0.05 indicating statistical significance.

3

|

3.1
vivo

RESULTS

|

Colocalization of CDK5 with Notch1 in

To determine the physiological relevance, we examined
the interaction of CDK5 and Notch1 in vivo using co-
immunoprecipitation. CDK5, p35, and Notch1 were expressed in BxPC-3 and HPAC cells (Figure 1A and B). We
observed that Notch1 copurified with CDK5 but not with
the IgG control, and CDK5 copurified with Notch1, demonstrating their specific binding and indicating a physical
interaction between CDK5 and Notch1 (Figure 1C and D).
To further determine whether CDK5 and Notch1 colocalize in vivo, immunostaining was performed. Staining with

F I G U R E 1 CDK5 physically associates with Notch1 in pancreatic cancer cells. The mRNA (A) and protein levels (B) of CDK5, p35, and
Notch1 were examined in BxPC-3 and HPAC cells. Cell lysates were immunoprecipitated with anti-CDK5 (C) or anti-Notch1 antibodies (D),
and immunoblotting was performed with anti-Notch1 and anti-CDK5 antibodies. Normal mouse or rabbit IgGs were used as negative controls.
Intracellular interactions of CDK5 and Notch1 in BxPC-3 (E) and HPAC (F) cells were visualized with a confocal microscope. The scale bar is
25 μM. CDK5, cyclin-dependent kinase 5
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CDK5-specific antibodies revealed that endogenous CDK5
was distributed through both the nucleus and cytoplasm
of cells. Colocalization of Notch1 and CDK5 in the cytoplasm of BxPC-3 and HPAC cells was observed by yellow
fluorescence when images of Cy3-stained anti-Notch1 and
FITC-stained anti-CDK5 immunocomplexes were merged
(Figure 1E and F).

3.2 | Phosphorylation of Notch1 peptide by
CDK5 in vitro
To determine the mechanism through which CDK5 regulates
Notch1 activation, we explored the potential phosphorylation
of Notch1 by CDK5. We analyzed Notch1 for the presence of
phosphorylation motifs using the NetPhos 3.1 Server (http://
www.cbs.dtu.dk/services/NetPhos/), which predicts protein
phosphorylation sites and potential kinase activity. This
analysis revealed the presence of 29 CDK5 phosphorylation
sites in human Notch1 with a score greater than 0.5. To determine whether CDK5 affects the phosphorylation of Notch1,
we determined whether CDK5 could phosphorylate a Notch1
peptide (Notch1 2128–2152, NP_060087.3) containing three
potential CDK5 phosphorylation sites (Figure 2A). An in
vitro kinase reaction demonstrated that T2132, S2136, and
S2141 were CDK5-phosphorylated sites in the Notch1 peptide (Figure 2B, C, and D). In the control experiment, the
peak of Notch1 peptide was observed at 2424.2 kD (Figure
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S1A) without CDK5/p25 kinase, which shifted to 2504.8 kD
with CDK5/p25 kinase (Figure S1B), indicating the specific
kinase activity of CDK5 on the Notch1 peptide.

3.3 | Inhibition of CDK5 activity impairs the
Notch1 pathway
To investigate whether CDK5 regulates Notch1 cleavage
and activation, CDK5 kinase activity was inhibited using
roscovitine, CDK5-
specific siRNA, or dominant-
negative
CDK5 (dnCDK5), respectively. The blockade of CDK5 by
roscovitine markedly inhibited the viability of both BxPC-3
and HPAC cells, as assessed by the MTT assay (Figure 3A).
After pretreatment with the indicated concentration of roscovitine for 1 h, levels of the 120 kD cleavage product of
Notch1 decreased in both cell lines, and full-length Notch1
only accumulated in HPAC cells (Figure 3B). Furthermore,
mRNA levels of the downstream Notch target genes, Hes1,
c-Met, and NFIA, were reduced in HPAC cells treated with
roscovitine for 6 h when compared with their levels in control cells, while only the Hes1 mRNA level was decreased in
BxPC3 cells. Roscovitine did not affect the Notch1 mRNA
level in either cell line (Figure 3C). Although, CDK5 is the
primary target of roscovitine, it also inhibits other CDKs,
such as CDK1, CDK2, CDK7, and CDK9. To determine
the specific effect of CDK5 blockade on Notch1, we used
an RNA interference (RNAi) strategy to antagonize CDK5

F I G U R E 2 Human Notch1 contains putative CDK5 phosphorylation sites and could be phosphorylated by CDK5. (A) The human Notch1
protein sequence (NP_060087) was analyzed using the Motif Scan program. The scores of three potential CDK5 phosphorylation sites in Notch1
2128–2152 residues are shown. (B, C, D) The phosphorylated Notch1 peptides were detected by liquid chromatography-mass spectrometry (LC-
MS). The phosphorylated S and T residues are indicated by lowercase letters. CDK5, cyclin-dependent kinase 5
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F I G U R E 3 Inhibition of CDK5 attenuates Notch1 signaling. (A) Cells were treated with 10 μM roscovitine. Cell viability was detected
using the MTT assay. Experiments at all-time points were assayed in triplicate. (B) Cells were treated with indicated roscovitine concentration for
1 h, and lysates were immunoblotted with Notch1 antibody to detect the full-length (Notch1/p300 kD) and 120 kD cleavage products of Notch1
(Notch1/p120 kD). (C) The mRNA levels of Notch1 signaling pathway effectors, Hes1, C-Met, NFIA, and Notch1, were detected in BxPC3 and
HPAC cells. Cells were treated with 10 μM roscovitine for 6 h. (D) Cells were transfected with CDK5-siRNA or negative control-RNA (NC) for
48 h. Protein levels of CDK5, Notch1 (Notch1/p120 kD), and β-actin were detected. (E) The mRNA levels of CDK5, Notch1, Hes1, and C-Met
were detected using qRT-PCR analysis. (F) HPAC cells were transiently transfected with CDK5 or CDK5-D144 N or CDK5-K33 T or pCMV
vector as control (Ctr). HA-tag antibody was used to detect CDK5 or CDK5 mutants. Protein levels of Notch1 (Notch1/p120 kD) and β-actin were
detected. CDK5, cyclin-dependent kinase 5; qRT-PCR, real-time quantitative reverse transcription-polymerase chain reaction

function. Similarly, the Notch1 level was profoundly decreased following RNAi knockdown of CDK5 in BxPC-3
and HPAC cells (Figure 3D). We further confirmed that
mRNA levels of the Notch1 target genes Hes1 and c-Met
were downregulated in CDK5 knockdown cells; however,
the mRNA level of Notch1 was not altered in either cell line
(Figure 3E).
To identify whether the regulation of Notch signaling was related to the kinase activity of CDK5, we treated
HPAC cells with the enforced expression of two dominant-
negative CDK5 (dnCDK5) proteins with an HA tag. The
dnCDK5 constructs were D144 N and K33 T kinase-dead
mutants that abolish the activation of endogenous CDK5 by
p35 when overexpressed.16 Consistent with results from the
RNAi strategy, HPAC cells expressing dnCDK5 constructs
presented significantly reduced levels of the 120 kD cleavage product of Notch1, indicating that CDK5 kinase activity

decreases Notch1 activation (Figure 3F). Furthermore, the
striking downregulation of the active form of Notch1 (NICD)
was observed in HPAC cells with knockdown of CDK5, and
could be restored by exogenous expression CDK5 (Figure 3).
Collectively, these results from multiple independent experiments confirmed that Notch1 activation is profoundly disrupted in CDK5-inhibited cells.

3.4 | Blockade of CDK5 and Notch
synergistically inhibits growth and migration
To determine the combined effect of CDK5 and Notch1
signaling on pancreatic cancer cells, we measured the effect of blocking CDK5 and/or Notch signaling on cell
proliferation and migration. DAPT is a γ-secretase inhibitor that inhibits the Notch signaling pathway. As several
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references have demonstrated that pharmacologic inhibition of CDK5 or Notch signaling had the same effect as
knockdown of CDK512,13,17 or Notch118 with siRNA. Both
pharmacologic and genetic inhibition mitigated growth in
pancreatic cancer cells. Here, we used the inhibitors to
explore the combined effect of CDK5 and Notch1 signaling on pancreatic cancer cells growth. Both DAPT and
roscovitine significantly inhibited HPAC cell growth
(Figure 4A) and migration (Figure 4C) when compared
with that of observed in control (DMSO-treated) cells.
The combined use of DAPT and roscovitine inhibited cell
growth and migration to a greater extent than treatment
with either agent alone (Figure 4A and C). These results
indicated that CDK5 inhibition sensitized HPAC cells to
more effectively inhibit cell proliferation and migration
via Notch inhibition.
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3.5 | CDK5 signaling is associated with
Notch signaling in PDAC
To verify the relevance of CDK5 signaling and Notch signaling in PDAC pathogenesis, we examined the expression
and interaction between CDK5 and Notch1 in clinical PDAC
specimens.
Based on the GEPIA database, we observed that Notch1,
CDK5, p35, and p39 were overexpressed in pancreatic adenocarcinoma (PAAD) samples (Figure 5A). The higher
Notch1 and p39 expressions correlated with poor overall
survival (Figure 5B). Consistent with their colocalization in
HPAC and BxPC3 cells, CDK5 and Notch1 colocalized in
PDAC specimens (Figure 5C). To investigate the potential
relationship between Notch and CDK5 signaling pathways in
patients with PDAC, Gene Set Enrichment Analysis (GSEA)

F I G U R E 4 Roscovitine and DAPT synergistically inhibit proliferation and migration. HPAC cells were treated with 10 μM roscovitine and/
or 2 μM DAPT. (A) Representative images showing the ability of HPAC cells to form colonies. Scale bar, 5 mm. (n = 3) (B) The histogram shows
the number of colonies formed. (C) Representative microscopic images presenting the effect of roscovitine and DAPT on the migration of HPAC
cells. Scale bar, 100 μM. (n = 3) (D) The semi-quantitative image analysis of migration is also presented. (E) The proposed model presenting the
function and mechanism of Notch1 regulated by CDK5. CDK5 positively regulates Notch1 signaling by phosphorylation, which in turn promotes
cell proliferation and migration. *p ≤ 0.05. CDK5, cyclin-dependent kinase 5
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F I G U R E 5 High CDK5 and p35 expression positively correlate with Notch signaling. (A) Analysis of differential expression of Notch1,
CDK5, p35, and p39 in normal and PDAC patients of using GEPIA. Tumor: n = 179; Normal: n = 171. (B) The survival curves of p35 and p39
were analyzed using GEPIA. (C) Representative double immunofluorescence staining of Notch1 (green) and CDK5 (red) in PDAC. (n = 3) (D) The
PDAC samples from TCGA database were ranked from low to high CDK5 or p35 expression groups, with quartile as boundary, the first 25% of the
samples were the low expression group, and the last 75% were the high expression group. Enrichment plots of gene expression signatures for the
Notch pathway activation was analyzed by GSEA according to CDK5 or p35 mRNA expression levels. CDK5, cyclin-dependent kinase 5; NES,
normalized enrichment score; FDR, false discovery rate

using the TCGA pancreatic cancer data set was performed to
assess Notch/CDK5 signaling. The GSEA outcomes revealed
that gene signatures of Notch signaling activation were enriched in patients with high CDK5 expression and high p35
expression (Figure 5D), suggesting a positive correlation between Notch and CDK5 signaling.

4

|

D IS C U SS ION

In the present study, we unraveled the physical association
between CDK5 and Notch1 and revealed their colocalization
in the cytoplasm. During intracellular processing, full-length
precursor Notch1 is transported to the trans-Golgi apparatus
and then cleaved into two linked peptides.6 As active CDK5/
p25 kinase is also located in Golgi membranes,8,9 the two
proteins might colocalize in the Golgi network. The phosphorylation of Notch1 by CDK5 could regulate the cleavage
of Notch1 by furin, as well as the maturation of the Notch1
receptor.
The inhibition of CDK5 by roscovitine significantly
reduced the 120 kD cleavage product of Notch1 in both
BxPC-3 and HPAC cells, which resulted in the significant accumulation of full-length Notch1 in HPAC cells (Figure 3A).
The different regulatory mechanisms of Notch activation
and heterogeneity in the transcriptional activation of target
genes in Notch-ON cells might account for this observation.5
Consistent with a previous study, our results suggest that
CDK5 has a positive effect on Notch1-dependent signaling.19
In the previous report, the authors revealed that CDK5 inhibition disrupted NICD generation and Notch function.19
Although, BxPC-3 and HPAC cells almost have the same
expression level of CDK5 protein, the full-length of Notch1/
p300 is a little higher in BxPC-3 (Figure 1B). In the following experiments, CDK5 inhibitor, CDK5-siRNA and CDK5
dominant-negative plasmids were used to explore the specific role of CDK5 in Notch1 signaling regulation, and the
results showed that Notch1 activation is profoundly disrupted
in CDK5-inhibited cells (Figure 3).
The inhibition of CDK5 decreased Notch1 cleavage but
not Notch1 expression, further downregulating Notch1 signaling (Figure 3). This indicates that Notch1 is regulated
by CDK5 at the post-transcriptional level. As CDK5 is a
proline-
directed serine/threonine kinase, Notch1 may be
regulated by CDK5 via phosphorylation. Notch is regulated

by various post-translational modifications, including phosphorylation, during multiple steps in the signaling pathway.
Phosphorylation occurs at multiple sites within the NICD
and regulates Notch signaling at different levels, such as
the maturation and localization of Notch1 in the cell membrane,20 translocation of the NICD into the nucleus,21 the
formation of a transcript complex and its binding to the promoter of the target genes,22 and the stability of the NICD.23
Three serine/threonine kinases that interact with Notch1
have been identified: GSK-3β, CDK8, and CK2.21,24,25 In
this study, we demonstrated that T2132, S2136, and S2141
are CDK5 phosphorylation sites in the Notch1 peptide.
CDK5 phosphorylates proteins at two consensus sequences:
(S/T)PX(K/H/R) and PX(S/T)P (where X is any amino
acid).26 Thus, T2132, S2136, and S2141 are potential candidate sites for CDK5 phosphorylation in Notch1 in vivo.
The future study needs to examine the identified Notch1
phosphorylation site with full-length Notch1 and the effect
of these sites mutations on Notch1 signaling regulated by
CDK5.
High expressions of CDK5, p35, or p39 and hyper-
activation of CDK5 signaling have been reported in several
cancers, including breast, ovarian, and colorectal cancer.27
Inhibition of CDK5 reportedly impairs tumorsphere formation and reduces tumor establishment.28 Based on the
GEPIA database, we observed that expression levels of
Notch1, CDK5, p35, and p39 are higher in PDAC tumor tissues than in normal tissues. High expression of Notch1 and
p39 correlated with poor prognosis and shorter patient survival in PDAC (Figure 5A and 5B). Collectively, these observations indicate that CDK5 and Notch1 act as oncogenes
in PDAC. Although, Notch1 is a target for PDAC therapy,
and the downregulation of Notch contributes to the inhibition, apoptosis, and metastasis of PDAC, clinical experience
with Notch pathway inhibitors remains relatively limited.29
Currently, several classes of Notch pathway inhibitors, including γ-secretase inhibitors (GSIs) and specific receptors
or antibodies, are in clinical development.29 Despite the
toxicity and limited therapeutic efficacy in clinical and preclinical studies, GSIs have revealed some clinical benefits;
for example, the GSI PF-0308414 reportedly demonstrates
promising clinical activity in a phase I dose-finding study.30
Some studies have suggested the combined use of low dose
GSIs and other drugs to target tumor cells, with the objectives of tolerable toxicity and better clinical responses.31
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Thus, designing rational combinations of therapeutic agents
to inhibit possible compensatory escape mechanisms could
be of particular importance. Furthermore, targeting several
pathways simultaneously may offer considerable benefits.
Notably, CDK5 inhibitors are already in pharmaceutical
development owing to the broad protumorigenic role of
CDK5.7 Therefore, the development of CDK5 and Notch
as combinational targets for pancreatic cancer could be
undertaken. Our data showed that the combination of roscovitine and DAPT exhibited stronger inhibition on PDAC
cell proliferation and migration than the inhibition of CDK5
or Notch function alone (Figure 4A and 4C). It has been
demonstrated that CDK5 inhibition can sensitize the neovascular endothelium of burgeoning tumors to allow more
effective anti-angiogenic treatment, such as the inhibition of
the Dll4/Notch pathway.19 Thus, the combinational inhibition of Notch and CDK5 is a potential strategy for PDAC
treatment. This combinational strategy need to be further
confirmed in xenograft mouse model.
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